Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer

Annals of Surgery

Volumn 258, Issue 2, 2013, Pages 336-346

  Oshima, Minoru ^a   Okano, Keiichi ^a   Muraki, Shinobu ^b   Haba, Reiji ^a   Maeba, Takashi ^b   Suzuki, Yasuyuki ^a   Yachida, Shinichi ^a,c  

^a KAGAWA UNIVERSITY   (Japan)

^b Ritsurin Hospital   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

immunohistochemistry; p16; p53; pancreatic ductal adenocarcinoma; Smad4 Dpc4

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; K RAS PROTEIN; PROTEIN P53; SMAD4 PROTEIN;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL DEDIFFERENTIATION; DISEASE FREE SURVIVAL; EXOME; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, P53; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RETROSPECTIVE STUDIES; SMAD4 PROTEIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880571709     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182827a65     Document Type: Article

References (49)

1. Ferlay J, Shin H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
3. Malvezzi M, Arf́e A, Bertuccio P, et al. European cancer mortality predictions for the year 2011. Ann Oncol. 2011;22:947-956.
4. Yamamoto Y, Sakamoto Y, Ban D, et al. Is celiac axis resection justified for T4 pancreatic body cancer? Surgery. 2012;151:61-69.
5. Ueno H,Kosuge T, Matsuyama Y, et al.Arandomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br JCancer. 2009;101:908-915.
6. Herman JM, SwartzMJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503-3510.
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
8. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579-586.
9. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114-1117.
10. Campbell PJ, Shinichi Y, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109-1113.
11. Ansari D, Rosendahl A, Elebro J, et al. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 2011;98:1041-1055.
12. Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007;11:229-243.
13. Frese KK, Tuveson DA, Maximizing mouse cancer models. Nat Rev Cancer. 2007;7:645-658.
14. Tuveson D, Hanahan D, Translational medicine: Cancer lessons from mice to humans. Nature. 2011;471:316-317.
15. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15:4674-4679.
16. Salek C, Minarikova P, Benesova L, et al. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res. 2009;29:1803-1810.
17. Geradts J, Hruban RH, Schutte M, et al. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol. 2000;8:71-79.
18. Baas IO, Mulder J-WR, Offerhaus GJA, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994;172:5-12.
19. Melhem MF, Law JC, el-Ashmawy L, et al. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol. 1995;146:1170-1177.
20. Sjogren S, Inganäs M, Norberg T, et al. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996;88:173-182.
21. Obata A, EuraM, Sasaki J, et al. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer. 2000;89:187-193.
22. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and nonfunctional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol. 2005;207:251-259.
23. Langeveld D, van Hattem WA, de Leng WWJ, et al. SMAD4 immunohistochemistry reflects genetic status in juvenile polyposis syndrome. Clin Cancer Res. 2010;16:4126-4134.
24. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36:173-184.
25. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol. 2000;156:37-43.
26. Iacobuzio-Donahue CA, Song J, Parmiagiani G, et al. Missense mutations of MADH4: Characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res. 2004;10:1597-1604.
27. Kanda M, Matthaei H,Wu J, et al. Presence of somatic mutations in most earlystage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:730 e9-733 e9.
28. Okano K, Kakinoki K, Akamoto S, et al. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol. 2011;17:231-235.
29. Murakami Y, Uemura K, Sudo T, et al. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. J Surg Oncol. 2012;106:174-180.
30. Iacobuzio-Donahue CA, FuB,Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-1813.
31. Yachida S, Sakamoto M, Imaida K, et al. p27(Kip1) is overexpressed in very early stages of hepatocarcinogenesis. Cancer Sci. 2008;99:2152-2159.
32. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression. Cancer Res. 1998;58:4740-4744.
33. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10:1199-1210; discussion 1210-1211.
34. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001;7:4115-4121.
35. Gerdes B, Ramaswamy A, Ziegler A, et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: An analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg. 2002;235:51-59.
36. Biankin AV, Morey AL, Lee C-S, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002;20:4531-4542.
37. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
38. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157-188.
39. Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20:3130-3146.
40. Giampieri S, Manning C, Hooper S, et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11:1287-1296.
41. Ding Z,Wu C-J, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470:269-273.
42. Crane CH,VaradhacharyGR,Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostainingwith pattern of disease progression. J Clin Oncol. 2011;29:3037-3043.
43. Lundin J, Nordling S, von Boguslawsky K, et al. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology. 1996;53:104-111.
44. Sinicrope FA, Evans DB, Leach SD, et al. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: Association with clinical outcome. Clin Cancer Res. 1996;2:2015-2022.
45. Hermanova M, Karasek P, Nenutil R, et al. Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma. Pancreas. 2009;38: 565-571.
46. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17:3112-3126.
47. QiuW, Sahin F, Iacobuzio-Donahue CA, et al. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget. 2011;2:862-873.
48. Iacobuzio-Donahue CA, Genetic evolution of pancreatic cancer: Lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2011;61:1085-1094.
49. Yamao K, Bhatia V, Mizuno N, et al. Interventional endoscopic ultrasonography. J Gastroenterol Hepatol. 2009;24:509-519.